Skip To Main Content
Jan-Willem Henning on Muck Rack

Jan-Willem Henning

As seen in: MDPI, The Lancet, Applied Radiation Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Jan-Willem Henning’s profile

Articles by Jan-Willem Henning

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective

|
By Jan-Willem Henning, Christine Brezden-Masley, Karen A. Gelmon, Stephen Chia
| MDPI
6. Diagnosis and Monitoring of T-DXd-Related ILD Current published recommendations for the early identification and management of T-DXd-related ILD in other jurisdictions do not necessarily fully apply to the Canadian health care environment, with variable timely access to pulmonary function tests (PFTs), high-resolution computed tomography (HRCT), and subspecialty respirology expertise.
Open in Who Shared Issue with article?

Clinical Considerations for the Integration of Adjuvant Olaparib into Practice for Early Breast Cancer: A Canadian Perspective

|
By Jan-Willem Henning, Tom McFarlane, Jean-François Boileau, Larissa Peck
| MDPI
2. Efficacy and Safety of Olaparib in Early Breast Cancer 2.1. The OlympiA Trial: Key Patient Characteristics and Eligibility Criteria OlympiA was a Phase 3, double-blinded, randomized trial evaluating the safety and efficacy of 12 months of adjuvant olaparib therapy versus placebo in high-risk, gBRCA-mutated, HER2-negative early breast cancer following definitive local treatment and adjuvant or neoadjuvant chemotherapy.
Open in Who Shared Issue with article?

Craniospinal Irradiation for Leptomeningeal Disease in Recurrent Breast Cancer

|
By Jaime K. Kwok, Megan Yaraskavitch, Jan-Willem Henning
| zurl.co
CASE SUMMARY We present a case of leptomeningeal disease (LMD) as the first recurrence of breast cancer in a 40-year-old woman with BRCA2 germline mutation. Initially diagnosed in 2017 with left-sided cT2N1 ER-positive, PR-negative, HER-2-negative invasive mammary carcinoma, she received neoadjuvant FEC-D chemotherapy and bilateral mastectomy with immediate reconstruction with near complete pathologic response (ypT1bN0).
Open in Who Shared Issue with article?

The chemo-gut study: investigating the long-term effects of chemotherapy on gut microbiota, metabolic, immune, psychological and cognitive parameters in young adult Cancer survivors; study protocol

|
By Raylene A Reimer, Julie M. Deleemans, Faye Chleilat, Jan-Willem Henning
| Biomed Central (BMC)
Abstract Background The gut microbiota is an important modulator of immune, metabolic, psychological and cognitive mechanisms. Chemotherapy adversely affects the gut microbiota, inducing acute dysbiosis, and alters physiological and psychological function. Cancer among young adults has risen 38% in recent decades. Understanding chemotherapy’s long-term effects on gut microbiota and psycho-physiological function is critical to improve survivors’ physical and mental health, but remains unexamined.
Open in Who Shared Issue with article?
Show More